Analyst Farzin Haque of Jefferies maintained a Buy rating on Vera Therapeutics (VERA – Research Report), with a price target of $58.00.Invest ...
TG Therapeutics is entering 2025 with investors accustomed to a beat-and-raise guidance policy and the company needs to deliver. Learn more on TGTX stock here.
Phase III Vivacity-MG3 trial shows that nipocalimab, an investigational FcRn blocker, significantly the improves symptoms of generalized myasthenia gravis with a manageable safety profile.
T cells play a pivotal role in the immune system by transforming into powerful effector cells that combat pathogens. This transformation requires rapid proliferation, during which DNA replication ...